Levothyroxine is a synthetic version of thyroxine (T4), the main hormone your thyroid gland produces, while liothyronine is a synthetic version of triiodothyronine (T3), the more potent hormone that actually drives most thyroid activity in your cells. The practical difference comes down to how your body uses them: levothyroxine acts as a slow-release reservoir that your tissues convert into T3 on their own schedule, whereas liothyronine delivers a direct hit of the active hormone that peaks quickly and fades within hours. This distinction shapes everything from how each drug is prescribed to who benefits from one, the other, or both.
What T4 and T3 Actually Do in Your Body
Your thyroid gland pumps out mostly T4, with only a small fraction of T3 released directly into the bloodstream. The majority of circulating T3 is produced outside the thyroid, in your liver, kidneys, brain, and other tissues, by enzymes that strip an iodine atom off of T4.
1PubMed. Mechanisms governing the relative proportions of thyroxine and 3,5,3′-triiodothyronine in thyroid secretionThis conversion system is run by a family of enzymes called deiodinases. Two of them (DIO1 and DIO2) activate T4 by turning it into T3, while a third (DIO3) does the opposite, breaking down T4 and T3 to keep levels from climbing too high.
2PubMed Central. Deiodinases and the Three Types of Thyroid Hormone Deiodination ReactionsThis means your body treats T4 like a warehouse supply and T3 like the finished product delivered to where it is needed. Different organs adjust their own local T3 levels independently, depending on what is happening in those cells at any given moment.
3PubMed. Deiodinases control local cellular and systemic thyroid hormone availabilityT3 is far more active than T4 at the cellular level. Thyroid hormone receptors bind T3 with roughly four to seven times greater affinity than T4, depending on the receptor type.
4PubMed Central. Insight Into Molecular Determinants of T3 vs T4 Recognition From Mutations in Thyroid Hormone Receptor α and β One receptor subtype shows a nearly 20-fold difference in how tightly it holds T4 compared with T3.5Molecular Endocrinology. The Ability of Thyroid Hormone Receptors to Sense T4 as an Agonist Depends on Receptor Isoform and on Cellular Cofactors That is why T4 is often called a “prohormone”: it does have some direct activity, but the heavy lifting is done after conversion to T3.
Why Levothyroxine Is the Default Treatment
When you swallow a levothyroxine tablet, the T4 enters your bloodstream gradually, peaking in a couple of hours and then lingering for days thanks to its long half-life of about a week. Your body then converts it into T3 at a pace dictated by those local deiodinase enzymes. This mimics the natural arrangement where the thyroid mainly secretes T4 and peripheral tissues handle the rest.
Guidelines from the American Thyroid Association (ATA) are clear: levothyroxine should remain the standard of care for hypothyroidism.
6PubMed Central. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacementThe reasons are straightforward. A once-daily pill gives stable blood levels that are easy to monitor with a simple blood test. Dosing can be fine-tuned in small increments. Decades of safety data back it up. And for most people, the conversion from T4 to T3 proceeds without a hitch, so there is no need to supply the active hormone directly.
How Liothyronine Differs in Practice
Liothyronine skips the conversion step entirely. Because it is already T3, it gets absorbed quickly and hits peak blood levels in about two to two and a half hours.
7Journal of Endocrinological Investigation. Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers But it also clears your system much faster, with a half-life of roughly one day versus a week for levothyroxine. That creates a pronounced spike-and-drop pattern. A study tracking 24-hour hormone profiles in patients on combination therapy found that free T3 levels surged about 42% within the first four hours after a dose, then fell back down, producing a wide peak-to-trough swing that does not resemble normal physiology.
8PubMed. Twenty-four hour hormone profiles of TSH, Free T3 and free T4 in hypothyroid patients on combined T3/T4 therapyThis volatility is the core pharmacological challenge with liothyronine. A healthy thyroid delivers T3 in a slow, steady drip. Taking liothyronine once or twice a day creates peaks that may overshoot the ideal range, followed by troughs that may dip below it. That is a very different experience from the flat, predictable levels that levothyroxine provides.
Persistent Symptoms Despite “Normal” Labs
For a significant number of patients, levothyroxine alone does not feel like enough. A UK study found that about 40% of treated hypothyroid patients still reported symptoms of hypothyroidism, compared with roughly 25% of matched controls.
9PubMed Central. Persistent hypothyroid symptoms in a patient with a normal thyroid stimulating hormone level A more recent practice assessment put the number at about one in four patients experiencing persistent or new hypothyroid symptoms even after their TSH had been brought into the normal range with levothyroxine.
10PubMed. Real Practice Assessment of Persistent Symptoms After Initiation of LevothyroxineWhy would symptoms persist when blood work looks fine? Several explanations have been proposed, and they are not mutually exclusive. Some patients may have impaired conversion of T4 to T3 in certain tissues, particularly the brain. Standard immunoassays used to measure free T3 and free T4 can also produce falsely normal results; more precise laboratory methods sometimes reveal that hormone levels are actually below the reference range in a subset of patients who test normal on the standard assay.
11PubMed Central. How reliable are free thyroid and total T3 hormone assays? And in some cases, the lingering symptoms may be related to the autoimmune disease that caused the hypothyroidism rather than to inadequate hormone levels.
Genetics and Who Might Need T3
One of the more compelling lines of research points to genetic variation in the DIO2 gene, which codes for the deiodinase enzyme responsible for converting T4 to T3 in the brain and other tissues. A common variant called Thr92Ala (sometimes written as rs225014) produces a version of DIO2 that does not work as efficiently. In animal studies, mice carrying this variant showed cognitive and neurological deficits during hypothyroidism that were corrected only when both T4 and T3 were given together; T4 alone was not enough to restore normal brain function.
12JCI Insight. Cognitive function in hypothyroidism: what is that deiodinase again?Human data from a randomized clinical trial added another layer. Researchers examined two gene variants together, one in DIO2 and another in a thyroid hormone transporter gene called MCT10. Among patients carrying neither variant, only 42% preferred combination therapy. Among those carrying one, 63% preferred it. And among patients carrying both, 100% preferred the T4-plus-T3 combination.
13PubMed Central. Hypothyroid Patients Encoding Combined MCT10 and DIO2 Gene Polymorphisms May Prefer L-T3 + L-T4 Combination Treatment These numbers come from a relatively small study, so they should not be taken as gospel. But they point toward a future where genetic testing might help identify which patients genuinely need T3 added to their regimen.
What the Combination Therapy Trials Actually Show
If genetics suggest some patients need T3, you might expect trials of combination therapy to show a clear win. The reality is murkier. A recent systematic review and meta-analysis compared levothyroxine alone with levothyroxine-plus-liothyronine across multiple studies. Quality of life scores showed no significant difference between the two approaches. There was, however, a small but statistically meaningful improvement in symptom scores favoring combination therapy.
14Journal of the Endocrine Society. MON-378 Comparative Efficacy of Levothyroxine Monotherapy and Levothyroxine/Liothyronine Combination Therapy for Hypothyroidism: A Systematic Review and Meta-AnalysisSomething interesting shows up in patient preference data. A separate meta-analysis found that even in trials where objective quality-of-life measures showed no difference between levothyroxine alone and the combination, patients still tended to prefer the combination regimen when asked which they liked better.
15PubMed Central. A Systematic Review and Meta-Analysis of Patient Preferences for Combination Thyroid Hormone Treatment for Hypothyroidism That disconnect between what the questionnaires measure and what patients say they prefer is one of the more vexing puzzles in thyroid medicine. It may mean the standard instruments are not capturing whatever is changing, or it may reflect a placebo-like effect from the perceived boost of receiving both hormones.
One limitation worth noting: predicting who will respond is frustratingly difficult. A trial that tried to use baseline T3 levels or changes in T3 during combination therapy to sort responders from non-responders came up empty. Neither measure correlated with who felt better on the combination.
16PubMed Central. Neither Baseline nor Changes in Serum Triiodothyronine during Levothyroxine/Liothyronine Combination Therapy Predict a Positive Response to This Treatment Modality in Hypothyroid Patients with Persistent SymptomsDesiccated Thyroid Extract
Before synthetic hormones existed, people with hypothyroidism swallowed dried animal thyroid tissue. Desiccated thyroid extract (DTE) is still available today and still has a devoted following. It contains both T4 and T3 along with smaller amounts of other thyroid-related molecules like T2 and calcitonin, making its hormonal profile broader than any synthetic formulation.
17PubMed Central. Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysisThe main downsides are batch-to-batch variability and a fixed T4-to-T3 ratio that does not match the ratio a healthy human thyroid produces. Animal thyroid glands contain proportionally more T3 relative to T4 than the human gland does, so DTE effectively delivers a larger T3 dose per unit of T4 than most patients’ own thyroids would. Whether the additional compounds in DTE (like T2) contribute anything clinically meaningful is still unclear.
Safety Considerations
Both medications are generally safe when dosed correctly, but the risks diverge in a few areas. The concern with liothyronine has historically centered on heart effects from those rapid T3 peaks. A controlled study in healthy volunteers, however, found no significant changes in heart rate, blood pressure, cardiac output, or energy expenditure during the four hours after a single liothyronine dose, even though serum T3 peaked at roughly four times the normal upper limit.
18PubMed Central. Acute Effects of Liothyronine Administration on Cardiovascular System and Energy Metabolism in Healthy Volunteers That does not mean chronic supraphysiologic T3 levels are harmless, but it does suggest that transient spikes from standard therapeutic doses are less dangerous than once feared.
Bone density is another concern with any thyroid hormone therapy. Long-term use of levothyroxine at TSH-suppressive doses (the higher doses used in thyroid cancer management to keep TSH near zero) has been linked to reduced bone mineral density and increased fracture risk.
19PubMed Central. Thyroid Hormone Diseases and Osteoporosis Replacement doses used for ordinary hypothyroidism, by contrast, do not appear to carry the same risk. A study comparing suppressive-dose patients with replacement-dose patients and healthy controls found that only the suppressive-dose group had significantly lower bone density.
20PubMed Central. The effect of replacement versus suppressive doses of levothyroxine on bone mineral densityPractical Dosing Quirks of Levothyroxine
Levothyroxine is notoriously fussy about how and when you take it. A systematic review documented that coffee, soy products, fiber, calcium supplements, and iron supplements all reduce its absorption.
21PubMed Central. Levothyroxine Interactions with Food and Dietary Supplements–A Systematic Review Calcium specifically reduces absorption by about 20% to 25%, regardless of the calcium formulation.
22PubMed Central. Absorption of levothyroxine when coadministered with various calcium formulations Proton pump inhibitors, bile acid sequestrants, and several other drug classes also interfere through different mechanisms, from physically binding the hormone in the gut to changing how fast the liver breaks it down.
23PubMed Central. Medications and Food Interfering with the Bioavailability of Levothyroxine: A Systematic ReviewThe standard advice is to take levothyroxine on an empty stomach, first thing in the morning, and wait 30 to 60 minutes before eating or taking other medications. That timing window is one reason some patients find the pill annoying to manage, and inconsistent adherence to the fasting requirement is itself a common cause of erratic thyroid levels.
Liothyronine has fewer documented food and drug interactions, in part because it has been studied less intensively in this regard. Its shorter half-life also means that missed-dose effects are more immediately noticeable, since there is less hormone stockpiled in circulation to buffer the gap.
Subclinical Hypothyroidism and When Treatment May Not Be Needed
Not everyone with a borderline-high TSH needs medication at all. Subclinical hypothyroidism, where TSH is elevated but free T4 is still in the normal range, is common and often self-resolving. Current evidence supports treating when TSH climbs above 10, but for milder cases a watch-and-wait approach is usually recommended to see whether levels normalize on their own.
24PubMed Central. To Treat or Not to Treat Subclinical Hypothyroidism, What Is the Evidence? A large population-based study also found that levothyroxine treatment of subclinical hypothyroidism did not reduce the risk of adverse kidney outcomes, pushing back against the idea that early treatment protects the kidneys.
25PubMed Central. Levothyroxine treatment for subclinical hypothyroidism and risk of adverse renal outcomes: a population-based cohort studyLiothyronine in Emergency and Critical Care
One setting where liothyronine has a clearer theoretical edge is in severe, life-threatening hypothyroidism, particularly myxedema coma. In critical illness, the body’s ability to convert T4 to T3 drops sharply. High-dose corticosteroids, which are often given alongside thyroid hormone in these emergencies, further suppress conversion. Adding liothyronine bypasses that bottleneck, delivering active hormone directly without depending on enzymes that are not working well.
26Journal of Clinical and Translational Endocrinology: Case Reports. Successful treatment of myxedema coma using levothyroxine and liothyronine in the setting of adrenal crisis and severe cardiogenic shock in a patient with apparent primary empty sella The evidence base here is thin, consisting mostly of case reports and expert opinion, since myxedema coma is rare enough that controlled trials are nearly impossible to run.
Liothyronine as an Antidepressant Booster
Psychiatrists have used liothyronine as an add-on to antidepressants for decades, even in patients with perfectly normal thyroid function. A review of the literature concluded that liothyronine is an effective augmentation strategy for depression when paired with antidepressants, particularly older tricyclic drugs and SSRIs.
27PubMed Central. Liothyronine for Depression: A Review and Guidance for Safety Monitoring The mechanism is not entirely clear, but T3 appears to influence serotonin and norepinephrine signaling in the brain independently of its metabolic effects.
Not everyone responds equally. Data from the STAR*D trial, one of the largest depression treatment studies ever conducted, suggested that older women responded to T3 augmentation better than older men, while younger men responded better than older men.
28Personalized Medicine in Psychiatry. T3 augmentation in major depressive disorder: Sex and age differences An earlier open-label study found that patients with atypical depression (marked by oversleeping, overeating, and heavy-limbed fatigue rather than insomnia and appetite loss) had dramatically higher response rates to T3 augmentation than those with typical depression.
29PubMed. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder This off-label use of liothyronine is one area where levothyroxine is not an interchangeable substitute; it is specifically T3 that appears to have the antidepressant-boosting properties.
The Push for a Better T3 Delivery System
The biggest practical barrier to wider liothyronine use is the spike-and-drop blood level pattern from current oral tablets. A healthy thyroid does not dump T3 into the bloodstream in boluses; it releases a trickle. Researchers have been working on sustained-release formulations that would smooth out those peaks, including slow-release tablets, T3-containing nanoparticles, subcutaneous implants, and even approaches involving stem cells to grow new thyroid tissue.
30PubMed Central. Sustained Release T3 Therapy: Animal Models and Translational ApplicationsIf a sustained-release T3 formulation eventually reaches the market, it could change the calculus for combination therapy entirely. Much of the current caution around liothyronine stems from the pharmacokinetic roller coaster of available tablets. A version that maintained stable T3 levels throughout the day would let researchers re-run the combination therapy trials under conditions that more closely resemble normal physiology, and the results might look quite different.
Thyroid Hormones During Pregnancy
Pregnant women with hypothyroidism are managed almost exclusively with levothyroxine. Maternal T4 crosses the placenta and plays a critical role in fetal brain development, particularly during the first trimester before the fetal thyroid begins functioning on its own. The fetus obtains a considerable proportion of its T4 from maternal circulation throughout gestation.
31JCI Insight. Transplacental thyroxine and fetal brain development Liothyronine is generally avoided in pregnancy because its short duration of action makes stable fetal hormone supply harder to maintain, and the spike-and-drop pattern is even less desirable when a developing brain is relying on that supply.
Levothyroxine doses often need to increase by 25% to 50% during pregnancy as blood volume rises and placental deiodinases consume additional T4. Most guidelines recommend checking thyroid function every four weeks during the first half of pregnancy and adjusting accordingly. After delivery, the dose can usually be dropped back to the pre-pregnancy level.
How Synthetic Levothyroxine Came to Dominate
For the first several decades of thyroid treatment, desiccated animal thyroid was the only option. The hormone thyroxine was crystallized in 1914, but it took until 1949 for a sodium salt formulation to be developed that could actually be absorbed orally.
32PubMed Central. Thyroxine and treatment of hypothyroidism: seven decades of experience Once synthetic levothyroxine proved that it could reliably deliver consistent doses, it gradually replaced animal-derived products as the first-line treatment. Today it is one of the most prescribed medications in the world, sitting comfortably in the top five in many countries.
Liothyronine’s story is less triumphant. It was synthesized around the same time, but its short half-life and the realization that T4 could be converted to T3 in the body made it seem redundant for routine use. The decades-long dominance of levothyroxine, combined with the ATA’s strong endorsement, has meant that liothyronine occupies a narrower therapeutic niche. Whether that niche should be wider is one of the more active debates in endocrinology, fueled by patient advocacy groups, emerging genetic research, and the persistent gap between “normal labs” and feeling well.